

PRESS RELEASE

*Paris and Toulouse, January 22nd, 2015***GENTICEL ANNOUNCES ITS FINANCIAL COMMUNICATION
CALENDAR FOR 2015**

GENTICEL (Euronext Paris and Brussels: FR0011790542 - GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces its financial communication agenda for 2015. This calendar of publication dates is for reference only; it is subject to change if necessary. Each publication will be released after Euronext market closing.

27 January 2015	Business & Cash Position Update 4 th Quarter 2014
2 March 2015	2014 Annual Results
28 April 2015	Business & Cash Position Update 1 st Quarter 2015
11 June 2015	Annual Shareholders Meeting
28 July 2015	Business & Cash Position Update 2 nd Quarter 2015
21 September 2015	2015 Half-Year Results
28 October 2015	Business & Cash Position Update 3 rd Quarter 2015

About Genticel

Genticel is a French biopharmaceutical company specialized in the development of therapeutic vaccines aimed at eliminating, at an early stage, the human papillomavirus (HPV) responsible for cervical cancer.

Genticel's most advanced candidate therapeutic vaccine, ProCervix, is currently in a Phase II clinical trial. ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18.

Genticel is based in Paris and Toulouse and was awarded the Deloitte Technology Fast 50 "Prix Biotech d'Avenir" (Most promising Biotech) in 2014.

Since April 4, 2014, Genticel shares have been listed on the regulated Euronext markets in Paris and Brussels. For more information, please visit www.genticel.com

**CONTACT GENTICEL**

Benedikt Timmerman
Chief Executive Officer
investors@genticel.com

USA INVESTOR CONTACT

Brian Stollar
Tel.: +1 (212) 915 2577
bstollar@lifesciadvisors.com

INVESTOR CONTACT

Corinne Puissant
Tel.: +33 (0)1 53 67 36 77
cpuissant@actus.fr

PRESS CONTACT

Alexandra Prisa
Tel.: +33 (0)1 53 67 36 90
aprisa@actus.fr